Travere Q2: FILSPARI sales +96% to $141M; FSGS launch drives 2,012 PSFs; net loss $34.8M

Travere Therapeutics, Inc.

U.S. net product sales $161.4M in Q2 2026, up from $94.8M; FILSPARI sales $141.1M (+96% YoY).
Net loss $34.8M ($0.37/share) vs $12.8M loss in Q2 2025; non-GAAP net loss $9.0M ($0.10/share).
Cash $489.2M; issued $525M of 0.5% convertible notes due 2032, repurchased $221M of 2029 notes.
In-licensed civorebrutinib from Everest Medicines for $112.5M upfront; plans to study in pMN, FSGS, MCD.
Phase 3 HARMONY for pegtibatinase in HCU enrolling; topline data expected 2H 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.